Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in Edwards Lifesciences Corp (NYSE:EW) by 4.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 30,766 shares of the medical research company’s stock after acquiring an additional 1,300 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Edwards Lifesciences were worth $4,479,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Optimum Investment Advisors purchased a new stake in shares of Edwards Lifesciences in the first quarter worth approximately $110,000. Private Capital Group LLC purchased a new stake in shares of Edwards Lifesciences in the second quarter worth approximately $112,000. IHT Wealth Management LLC raised its stake in shares of Edwards Lifesciences by 84.6% in the first quarter. IHT Wealth Management LLC now owns 932 shares of the medical research company’s stock worth $126,000 after purchasing an additional 427 shares during the last quarter. Well Done LLC purchased a new stake in shares of Edwards Lifesciences in the first quarter worth approximately $152,000. Finally, Fagan Associates Inc. purchased a new stake in shares of Edwards Lifesciences in the second quarter worth approximately $201,000. Institutional investors and hedge funds own 82.28% of the company’s stock.

In other news, CFO Scott B. Ullem sold 25,000 shares of the firm’s stock in a transaction on Wednesday, June 6th. The stock was sold at an average price of $141.07, for a total value of $3,526,750.00. Following the completion of the transaction, the chief financial officer now directly owns 41,265 shares of the company’s stock, valued at $5,821,253.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael A. Mussallem sold 32,900 shares of the firm’s stock in a transaction on Tuesday, July 31st. The stock was sold at an average price of $141.86, for a total value of $4,667,194.00. Following the completion of the transaction, the chief executive officer now directly owns 43,126 shares of the company’s stock, valued at $6,117,854.36. The disclosure for this sale can be found here. Over the last three months, insiders have sold 150,800 shares of company stock valued at $21,685,380. 1.84% of the stock is owned by corporate insiders.

Shares of NYSE EW opened at $141.73 on Friday. Edwards Lifesciences Corp has a 1-year low of $100.20 and a 1-year high of $156.87. The firm has a market cap of $29.55 billion, a price-to-earnings ratio of 33.28, a PEG ratio of 2.05 and a beta of 0.60. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.86 and a quick ratio of 1.47.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, July 26th. The medical research company reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.11. Edwards Lifesciences had a return on equity of 29.11% and a net margin of 19.59%. The business had revenue of $972.00 million during the quarter, compared to analyst estimates of $968.32 million. During the same period in the prior year, the company earned $1.08 earnings per share. Edwards Lifesciences’s revenue was up 10.0% compared to the same quarter last year. analysts anticipate that Edwards Lifesciences Corp will post 4.66 earnings per share for the current year.

Several analysts have recently commented on the company. JPMorgan Chase & Co. increased their price objective on Edwards Lifesciences from $133.00 to $150.00 and gave the stock a “neutral” rating in a research note on Friday, July 27th. Northland Securities reaffirmed a “hold” rating and set a $120.00 price target on shares of Edwards Lifesciences in a research report on Friday, July 27th. Jefferies Financial Group reaffirmed a “buy” rating and set a $168.00 price target on shares of Edwards Lifesciences in a research report on Friday, July 27th. Sanford C. Bernstein started coverage on Edwards Lifesciences in a research report on Wednesday, June 27th. They set a “market perform” rating and a $165.00 price target for the company. Finally, ValuEngine raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Tuesday, June 12th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $152.45.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Featured Article: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.